Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Launched by CASE COMPREHENSIVE CANCER CENTER · Jul 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a faster way to deliver a type of radiation treatment called stereotactic body radiation therapy (SBRT) for people whose cancer has spread to a few spots in the body (up to five), a condition known as oligometastatic disease. Normally, preparing for this treatment can take up to a week or more because it requires a special CT scan to plan the radiation. This study is testing whether using recent scans that patients already had, instead of scheduling a new CT scan, can safely speed up the treatment process and help people start their radiation sooner.

People who might be eligible for this study are adults with up to five active cancer spots, who are healthy enough to receive SBRT and have had a recent CT, MRI, or PET scan of the areas to be treated. Participants should have a life expectancy of at least three months and be able to understand and agree to the study. If you join, you can expect to receive this quicker, “simulation-free” radiation treatment, which aims to make getting care easier and faster without compromising safety. This approach has worked well for people with more advanced cancers, and this study will help doctors learn if it’s also safe and effective for those with limited spread.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have histologically, cytologically, or radiographically or confirmed cancer that is oligometastastatic (defined in this protocol as up to 5 active sites of disease at time of trial enrollment). Note that previous ablative therapy to the treatment site (excluding prior external beam radiation) is permitted, such as previous microwave ablation or radiofrequency ablation.
• • Age ≥18 years.
• • Performance status: Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
• • Estimated life expectancy of at least 3 months
• • Participants must be considered a candidate for SBRT by the treating physician
• • Prior chemotherapy or biological treatment is allowed, but any active oncological treatment should be stopped at least 1 week prior to radiation therapy and renewed no sooner than 1 week following radiation therapy, with the exception of endocrine therapies, which can continue through radiation treatment.
• • Participants must have the ability to understand and the willingness to sign a written informed consent document.
• • Participants must have a diagnostic CT, MRI, or PET/CT of the site(s) intended for treatment, with or without contrast, acquired no more than 30 days prior to study consent.
• Exclusion Criteria:
• • Prior radiotherapy to any site overlapping with the projected site for protocol treatment.
• • Participants with isolated vertebral metastases except for sacral spine; participants with osseous spine disease can be treated upon this protocol, but those sites (cervical, thoracic, lumbar spine) are not permitted for treatment upon this study. Such participants could be enrolled for treatment to other, concurrent (e.g., visceral, or non-spine bone) disease on this study.
• • Pregnant or breastfeeding women are excluded from this study.
• • Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by the treating physician or protocol principal investigator (PI), documentation of this exception is sufficient in lieu of a pregnancy test.